ESSENTIAL THROMBOCYTHEMIA WITH CALR MUTATION

Clinical trials for ESSENTIAL THROMBOCYTHEMIA WITH CALR MUTATION explained in plain language.

Never miss a new study

Get alerted when new ESSENTIAL THROMBOCYTHEMIA WITH CALR MUTATION trials appear

Sign up with your email to follow new studies for ESSENTIAL THROMBOCYTHEMIA WITH CALR MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for rare blood cancer: targeted drug enters final testing

Disease control Not yet recruiting

This study tests a new drug, INCA033989, against the best current treatments for people with essential thrombocythemia (a rare blood cancer) who have a specific gene change called CALR mutation and have already tried other therapies. The goal is to see if the new drug can better …

Matched conditions: ESSENTIAL THROMBOCYTHEMIA WITH CALR MUTATION

Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control

Last updated Jun 15, 2026 19:06 UTC

ESSENTIAL THROMBOCYTHEMIA WITH CALR MUTATION

Get alerted when new ESSENTIAL THROMBOCYTHEMIA WITH CALR MUTATION trials appear

New hope for rare blood cancer: targeted drug enters final testing